These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 33217824)
1. Identification of grade-related genes and construction of a robust genomic-clinicopathologic nomogram for predicting recurrence of bladder cancer. Peng X; Wang J; Li D; Chen X; Liu K; Zhang C; Lai Y Medicine (Baltimore); 2020 Nov; 99(47):e23179. PubMed ID: 33217824 [TBL] [Abstract][Full Text] [Related]
2. Four novel biomarkers for bladder cancer identified by weighted gene coexpression network analysis. Yan X; Guo ZX; Liu XP; Feng YJ; Zhao YJ; Liu TZ; Li S J Cell Physiol; 2019 Aug; 234(10):19073-19087. PubMed ID: 30927274 [TBL] [Abstract][Full Text] [Related]
3. Identifying the mRNAs associated with Bladder cancer recurrence. Cao H; Cheng L; Yu J; Zhang Z; Luo Z; Chen D Cancer Biomark; 2020; 28(4):429-437. PubMed ID: 32390597 [TBL] [Abstract][Full Text] [Related]
4. Opa interacting protein 5 acts as an oncogene in bladder cancer. He X; Hou J; Ping J; Wen D; He J J Cancer Res Clin Oncol; 2017 Nov; 143(11):2221-2233. PubMed ID: 28752236 [TBL] [Abstract][Full Text] [Related]
5. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer. Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775 [TBL] [Abstract][Full Text] [Related]
6. Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer. Li X; Fu S; Huang Y; Luan T; Wang H; Wang J BMC Cancer; 2021 Nov; 21(1):1267. PubMed ID: 34819038 [TBL] [Abstract][Full Text] [Related]
7. Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer. Wang B; Tong F; Zhai C; Wang L; Liu Y; Wang J Dis Markers; 2021; 2021():3385058. PubMed ID: 34721733 [TBL] [Abstract][Full Text] [Related]
8. Bioinformatics Analysis Identified Key Molecular Changes in Bladder Cancer Development and Recurrence. Chen Q; Hu J; Deng J; Fu B; Guo J Biomed Res Int; 2019; 2019():3917982. PubMed ID: 31828101 [No Abstract] [Full Text] [Related]
9. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer. Wang J; Shen C; Dong D; Zhong X; Wang Y; Yang X Int Immunopharmacol; 2021 Jan; 90():107146. PubMed ID: 33189610 [TBL] [Abstract][Full Text] [Related]
10. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram. Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443 [TBL] [Abstract][Full Text] [Related]
11. PLK1 as one novel target for the poor prognosis of bladder cancer: An observational study. Liu B; Meng LB; Su JZ; Fan B; Zhao SB; Wang HY; Li T; Wang TY; Zhang AL; Ni XC Medicine (Baltimore); 2022 Sep; 101(39):e30723. PubMed ID: 36181054 [TBL] [Abstract][Full Text] [Related]
12. Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. Kang HW; Seo SP; Byun YJ; Piao XM; Kim YH; Jeong P; Ha YS; Kim WT; Kim YJ; Lee SC; Moon SK; Choi YH; Yun SJ; Kim WJ Clin Genitourin Cancer; 2018 Aug; 16(4):274-280. PubMed ID: 29571585 [TBL] [Abstract][Full Text] [Related]
13. The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA. Shen C; Liu J; Wang J; Yang X; Niu H; Wang Y Dis Markers; 2020; 2020():4312629. PubMed ID: 32454905 [No Abstract] [Full Text] [Related]
14. Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer. Mitra AP; Lam LL; Ghadessi M; Erho N; Vergara IA; Alshalalfa M; Buerki C; Haddad Z; Sierocinski T; Triche TJ; Skinner EC; Davicioni E; Daneshmand S; Black PC J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25344601 [TBL] [Abstract][Full Text] [Related]
15. Novel Biomarkers Associated With Progression and Prognosis of Bladder Cancer Identified by Co-expression Analysis. Wang Y; Chen L; Ju L; Qian K; Liu X; Wang X; Xiao Y Front Oncol; 2019; 9():1030. PubMed ID: 31681575 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer. Zhang Z; Zhang G; Gao Z; Li S; Li Z; Bi J; Liu X; Li Z; Kong C BMC Cancer; 2017 Dec; 17(1):861. PubMed ID: 29246203 [TBL] [Abstract][Full Text] [Related]
17. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer. Duan W; Du L; Jiang X; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Zhang X; Pan H; Yang Y; Wang C Oncotarget; 2016 Nov; 7(48):78850-78858. PubMed ID: 27793008 [TBL] [Abstract][Full Text] [Related]
18. External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. Brooks M; Godoy G; Sun M; Shariat SF; Amiel GE; Lerner SP J Urol; 2016 Feb; 195(2):283-9. PubMed ID: 26343350 [TBL] [Abstract][Full Text] [Related]
19. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data. Orucevic A; Bell JL; King M; McNabb AP; Heidel RE Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185 [TBL] [Abstract][Full Text] [Related]
20. Development of a novel prognostic signature for predicting the overall survival of bladder cancer patients. Tang H; Kan L; Ou T; Chen D; Dou X; Wu W; Ji X; Wang M; Zong Z; Mo H; Zhang X; Xiong D Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32441304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]